| El Encanto Healthcare Center | |
| 555 South El Encanto Road, City Of Industry, California 91745 | |
| (626) 336-1274 | |
| Name | El Encanto Healthcare Center |
|---|---|
| Location | 555 South El Encanto Road, City Of Industry, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 185 |
| Occupancy Rate | 32% |
| Medicare ID (CCN) | 555395 |
| Legal Business Name | Industry Convalescent Hospital |
| Ownership Type | Non Profit - Other |
| NPI Number | 1205839081 |
| Organization Name | INDUSTRY CONVALESCENT HOSPITAL |
| Doing Business As | EL ENCANTO HEALTHCARE & HABILITATION CENTER |
| Address | 555 S. El Encanto Rd, City Of Industry, CA 91745 |
| Phone Number | 626-336-1274 |
News Archive
Just as no two humans are the same, a Purdue University scientist has shown treating mice more as individuals in laboratory testing cuts down on erroneous results and could significantly reduce the cost of drug development.
Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.
Resistance to antifungal therapy of genital-infection causing Candida species may be an increasing problem, suggests research presented at the European Academy of Dermatology and Venereology annual congress in Prague, Czech Republic.
An international research team has investigated interactions in different states of consciousness and has discovered that patients with severely impaired consciousness show a pathological or uncontrolled communication between resting-state networks.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Just as no two humans are the same, a Purdue University scientist has shown treating mice more as individuals in laboratory testing cuts down on erroneous results and could significantly reduce the cost of drug development.
Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.
Resistance to antifungal therapy of genital-infection causing Candida species may be an increasing problem, suggests research presented at the European Academy of Dermatology and Venereology annual congress in Prague, Czech Republic.
An international research team has investigated interactions in different states of consciousness and has discovered that patients with severely impaired consciousness show a pathological or uncontrolled communication between resting-state networks.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10.73 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.7 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 37.5 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.44 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.54 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.16 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.11 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.54 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.85 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 52.38 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.27 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 3.61 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.84 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 61.14 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 78.49 | 82.93 |
News Archive
Just as no two humans are the same, a Purdue University scientist has shown treating mice more as individuals in laboratory testing cuts down on erroneous results and could significantly reduce the cost of drug development.
Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.
Resistance to antifungal therapy of genital-infection causing Candida species may be an increasing problem, suggests research presented at the European Academy of Dermatology and Venereology annual congress in Prague, Czech Republic.
An international research team has investigated interactions in different states of consciousness and has discovered that patients with severely impaired consciousness show a pathological or uncontrolled communication between resting-state networks.
› Verified 7 days ago
El Encanto Healthcare Center Location: 555 South El Encanto Road, City Of Industry, California 91745 Phone: (626) 336-1274 |